E.U. investigates Ozempic and weight-loss drug Saxenda after reports of suicidal thoughts

The European Medicines Agency is investigating Novo Nordisk’s diabetes drug Ozempic and weight-loss treatment Saxenda after Iceland’s health regulator flagged three cases of patients thinking about suicide or self-harm. Shares of the Danish drugmaker fell 1% on Monday following the news. A European Medicines Agency, or EMA, safety committee is looking into adverse events raised…